01—Abstract
Summary
Summary of the 8-K filed May 29, 2024. Cited figures are marked; the original filing is the authoritative source.
On May 28, 2024, ConocoPhillips (COP) entered into a definitive Agreement and Plan of Merger to acquire Marathon Oil Corporation (MRO) in an all-stock transaction.
Under the terms, each Marathon share converts into 0.2550 shares of ConocoPhillips common stock. The companies describe an enterprise value of $22.5 billiona, including $5.4 billion of net debt, and a 14.7% premium to Marathon's May 28, 2024 closing price. The deal is expected to close in the fourth quarter of 2024, subject to Marathon stockholder approval, HSR and other regulatory clearances, effectiveness of an S-4 registration statement, and NYSE listing authorization.
Management expects the transaction to be immediately accretive to earnings, cash flow, free cash flow, and return of capital per share, and targets at least $500 millionb of run-rate cost and capital synergies within the first full year after closing. The companies cite over 2 billion barrels of added resource with an estimated point-forward cost of supply below $30 per barrel WTI. Separately, and independent of the deal, ConocoPhillips plans a 34% increase in its ordinary base dividend to $0.78 per share starting in Q4 2024.
For investors, the key items are the all-stock structure, which dilutes existing holders but avoids added leverage, the capital return commitments (over $7 billionc of buybacks in the first full year post-close, over $20 billion over three years, at recent commodity prices), and the deal protections. Marathon would owe ConocoPhillips a $557 million termination fee in specified circumstances, or $86 million if its stockholders reject the merger. The filing itself is a summary of the merger agreement, and management's accretion and synergy claims are forward-looking statements that depend on closing and commodity prices.
02—Key points
Key Highlights
- All-stock acquisition of Marathon Oil at a fixed exchange ratio of 0.2550 COP shares per MRO share, with a stated enterprise value of $22.5 billion including $5.4 billion of net debt
- Implied 14.7% premium to Marathon's May 28, 2024 closing share price and 16.0% premium to its prior 10-day VWAP
- Management expects the deal to be immediately accretive to earnings, cash flows, free cash flow, and return of capital per share
- At least $500 million of run-rate cost and capital synergies targeted within the first full year after closing, from G&A, operating cost, and capital efficiency savings
- Over 2 billion barrels of added resource with an estimated point-forward cost of supply below $30/bbl WTI, adjacent to COP's U.S. unconventional position
- Post-close buyback plan of over $7 billion in the first full year (vs. over $5 billion standalone) and over $20 billion over three years, with intent to retire the equivalent of newly issued shares within 2–3 years
- Standalone ordinary base dividend increase of 34% to $0.78 per share starting Q4 2024, independent of the transaction; termination fees of $557 million (general) and $86 million (Marathon stockholder vote failure)
03—Questions
Frequently Asked Questions
What are Marathon shareholders receiving in this deal?
Each outstanding share of Marathon Oil common stock (other than certain excluded shares) will be converted into the right to receive 0.2550 shares of ConocoPhillips common stock. The transaction is all-stock, so no cash consideration is part of the stated structure.
When is the transaction expected to close, and what could stop it?
The companies expect closing in the fourth quarter of 2024. Closing requires Marathon stockholder approval, expiration or termination of the HSR waiting period, certain other regulatory approvals, the effectiveness of ConocoPhillips' Form S-4, and NYSE listing authorization for the new shares, along with customary representations, covenants, and no material adverse effect. The agreement can be terminated if closing has not occurred by May 28, 2025, with extensions to November 28, 2025 and May 28, 2026 if only regulatory approvals remain outstanding.
What are the termination fees and when do they apply?
Marathon would pay ConocoPhillips $557 million if it terminates to accept a superior proposal, if ConocoPhillips terminates after a Marathon board change of recommendation, or if ConocoPhillips terminates due to a material breach of Marathon's non-solicitation obligations. If the merger fails because Marathon stockholders do not approve it, Marathon would pay $86 million. ConocoPhillips can receive only one fee, net of any expense reimbursement.
How will this deal affect ConocoPhillips' capital return program?
Management says the deal is immediately accretive to return of capital per share and expects to repurchase over $7 billion of shares in the first full year after closing, compared with over $5 billion standalone, and over $20 billion over three years, assuming recent commodity prices. It also plans to retire the equivalent amount of newly issued equity within two to three years. The company reiterates a framework of returning more than 30% of cash from operations to shareholders.
What risks should investors weigh beyond the headline accretion claims?
The accretion, synergy, and buyback figures are forward-looking and depend on closing, integration success, and commodity prices. Risks include failure to obtain Marathon stockholder or regulatory approvals, integration difficulties, retention of key personnel, the value of the 0.2550 exchange ratio if ConocoPhillips' share price moves, and exposure to oil and gas price declines. The 8-K also notes that the merger agreement's representations are qualified for risk allocation and that investors should consult the S-4 and proxy statement/prospectus when filed.
04—Continue